Last reviewed 2026-06-02 · How we verify

Vita 6

Muhammad Aamir Latif · Phase 1 active Small molecule ✓ Verified Jun 2026

Vita 6 is a Small molecule drug developed by Muhammad Aamir Latif. It is currently in Phase 1 development.

The Qualis contact lens is a soft, hydrophilic contact lens designed for daily wear, and it has been studied for its safety and effectiveness in treating refractive errors. Additionally, the Qualis contact lens has been studied in relation to conditions such as hypovitaminosis, vitamin A deficiency, dry eye, and cataract, although the primary intervention in these studies was vitamin A supplementation, not the contact lens itself.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Vita 6
Sponsor	Muhammad Aamir Latif
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vita 6 CI brief — competitive landscape report
Vita 6 updates RSS · CI watch RSS
Muhammad Aamir Latif portfolio CI

Frequently asked questions about Vita 6

What is Vita 6?

Vita 6 is a Small molecule drug developed by Muhammad Aamir Latif.

Who makes Vita 6?

Vita 6 is developed by Muhammad Aamir Latif (see full Muhammad Aamir Latif pipeline at /company/muhammad-aamir-latif).

What development phase is Vita 6 in?

Vita 6 is in Phase 1.

Manufacturer: Muhammad Aamir Latif — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing